DK2470545T3 - Anhydrate former af et pyridinderivat - Google Patents

Anhydrate former af et pyridinderivat

Info

Publication number
DK2470545T3
DK2470545T3 DK10747619.4T DK10747619T DK2470545T3 DK 2470545 T3 DK2470545 T3 DK 2470545T3 DK 10747619 T DK10747619 T DK 10747619T DK 2470545 T3 DK2470545 T3 DK 2470545T3
Authority
DK
Denmark
Prior art keywords
pyridine derivative
anhydrate forms
anhydrate
forms
pyridine
Prior art date
Application number
DK10747619.4T
Other languages
Danish (da)
English (en)
Inventor
Andrew Simon Craig
Salima Zarah Ismail
Ronnie Maxwell Lawrence
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Application granted granted Critical
Publication of DK2470545T3 publication Critical patent/DK2470545T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK10747619.4T 2009-08-27 2010-08-25 Anhydrate former af et pyridinderivat DK2470545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
DK2470545T3 true DK2470545T3 (da) 2014-01-13

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10747619.4T DK2470545T3 (da) 2009-08-27 2010-08-25 Anhydrate former af et pyridinderivat

Country Status (18)

Country Link
US (1) US8796269B2 (enExample)
EP (1) EP2470545B1 (enExample)
JP (3) JP2013503134A (enExample)
KR (1) KR20120056258A (enExample)
CN (1) CN102639536B (enExample)
AU (1) AU2010288502B2 (enExample)
BR (1) BR112012003435A2 (enExample)
CA (1) CA2772168C (enExample)
DK (1) DK2470545T3 (enExample)
EA (1) EA021411B1 (enExample)
ES (1) ES2440938T3 (enExample)
IL (1) IL217922A (enExample)
IN (1) IN2012DN01292A (enExample)
MX (1) MX2012002369A (enExample)
PL (1) PL2470545T3 (enExample)
SG (1) SG178231A1 (enExample)
WO (1) WO2011023733A1 (enExample)
ZA (1) ZA201200812B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796269B2 (en) * 2009-08-27 2014-08-05 Nerre Therapeutics Limited Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same
EP3915560A1 (en) * 2014-06-25 2021-12-01 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
JP6902682B2 (ja) * 2015-05-18 2021-07-14 カンディー セラピューティクス リミテッド 性ホルモン依存性疾患を治療するためのnk−1/nk−3受容体デュアルアンタゴニスト
KR20190091455A (ko) * 2016-12-15 2019-08-06 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 화합물
RS65257B1 (sr) 2018-03-14 2024-03-29 Kandy Therapeutics Ltd Nova farmaceutska formulacija koja sadrži dvojne antagoniste receptora nk-1/nk-3
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
EP4058433A1 (en) 2019-11-15 2022-09-21 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
HRP20050664A2 (en) * 2003-01-31 2006-12-31 F. Hoffmann - La Roche Ag NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-A(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
BRPI0412291A (pt) * 2003-07-03 2006-09-19 Hoffmann La Roche antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
PT1928886E (pt) * 2005-09-09 2011-07-14 Glaxosmithkline Llc Derivados de piridina e sua utilização para o tratamento de distúrbios psicóticos
AU2008346110A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
US8796269B2 (en) * 2009-08-27 2014-08-05 Nerre Therapeutics Limited Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
MX2012002369A (es) 2012-03-29
EP2470545A1 (en) 2012-07-04
ES2440938T3 (es) 2014-01-31
JP2013503134A (ja) 2013-01-31
AU2010288502A1 (en) 2012-02-23
CA2772168A1 (en) 2011-03-03
CA2772168C (en) 2019-01-08
KR20120056258A (ko) 2012-06-01
CN102639536B (zh) 2015-03-18
ZA201200812B (en) 2013-03-27
US8796269B2 (en) 2014-08-05
JP2017193564A (ja) 2017-10-26
JP2016000739A (ja) 2016-01-07
CN102639536A (zh) 2012-08-15
IL217922A (en) 2016-06-30
IL217922A0 (en) 2012-03-29
US20120157450A1 (en) 2012-06-21
AU2010288502B2 (en) 2013-12-12
EP2470545B1 (en) 2013-10-09
EA021411B1 (ru) 2015-06-30
SG178231A1 (en) 2012-03-29
IN2012DN01292A (enExample) 2015-06-05
EA201270302A1 (ru) 2012-07-30
JP6404186B2 (ja) 2018-10-10
PL2470545T3 (pl) 2014-03-31
BR112012003435A2 (pt) 2016-02-23
WO2011023733A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
DK2470545T3 (da) Anhydrate former af et pyridinderivat
LTPA2021505I1 (lt) Pakeistojo policiklinio karbamoilpiridono darinio provaistas
HUS2000005I1 (hu) Diamino-heterociklusos karboxamid-vegyület
EP2404918A4 (en) pyridine
EP2519522A4 (en) SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS
DK2262793T3 (da) Krystallinske former af nilotinib-hci
HRP20180646T1 (hr) Dispiropirolidinski derivat
DK2268160T3 (da) Emulsioner omfattende et PEG-derivat af tokoferol
ECSP12011999A (es) Derivados benzamida sustituidos
DK3703369T3 (da) Fusion af prøveområder
FI20095666A0 (fi) Hitsauksen optimointi
DK2404485T3 (da) Automatisk konfigurering af en belysning
BRPI1011683A2 (pt) derivado isoquinolina substituída
DK2260153T3 (da) Brandbeskyttelse af et strukturelt element
EP2397480A4 (en) DIAZEPINEDIONEDERIVATE
EP2508513A4 (en) 2-PYRIDONES COMPOUNDS
BR112012005960A2 (pt) n-fenil-1-(4-piridinil)-1h-pirazol-3-aminas substituídas
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BR112012002807A2 (pt) derivados de 5-flúor-2-oxopirimidina-1(2h)-caboxilato
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
EP2401281A4 (en) PYRIMIDINPYRIMIDOINDAZOLDERIVAT
EP2519519A4 (en) Substituted Naphthalenyl-pyrimidine compounds
PL2488157T3 (pl) Ulepszone preparaty
DK2217006T3 (da) Et høreapparat
EP2476533A4 (en) Mold release agent